Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples